Research Article
Antithrombotic Therapy in Patients with Acute Coronary Syndrome in the Intermountain Heart Collaborative Study
Table 3
Patient characteristics by postdischarge AT therapy.
| | | No antiplatelet | Single antiplatelet | Dual antiplatelet | | | No AC | AC | No AC | AC | No AC | AC | | | | | | | | |
| | Age (mean ± std) | 64.9 ± 15.18 | 67.6 ± 12.76 | 64.3 ± 12.29 | 67.7 ± 11.98 | 63.8 ± 12.26 | 67.8 ± 12.50 | | Male | 61.2% | 69.6% | 70.7% | 66.5% | 73.7% | 76.6% | | Caucasian | 94.2% | 91.3% | 87.9% | 90.5% | 89.5% | 92.3% | | Body Mass Index (mean ± std) | 28.2 ± 5.97 | 30.6 ± 8.86 | 29.9 ± 7.27 | 30.2 ± 18.39 | 29.7 ± 6.81 | 30.6 ± 13.87 | | Family history of early CVD | 31.1% | 17.4% | 43.7% | 37.4% | 45.5% | 37.0% | | Smoking history | 8.7% | 26.1% | 16.0% | 12.8% | 16.3% | 17.2% | | Prior MI | 19.4% | 8.7% | 15.4% | 17.3% | 16.7% | 17.9% | | Comorbidities | | | | | | | | COPD | 14.6% | 13.0% | 6.7% | 10.1% | 7.1% | 12.1% | | CVA | 6.8% | 8.7% | 3.9% | 10.1% | 3.5% | 7.7% | | Diabetes | 32.0% | 17.4% | 29.3% | 25.7% | 24.8% | 28.6% | | Heart failure | 38.8% | 56.5% | 29.4% | 49.2% | 20.1% | 42.9% | | Hypercoagulability | 1.0% | 4.3% | 0.0% | 1.1% | 0.1% | 0.7% | | Hyperlipidemia | 64.1% | 56.5% | 64.7% | 57.5% | 65.6% | 60.1% | | Hypertension | 66.0% | 52.2% | 65.9% | 59.8% | 65.6% | 65.2% | | Major bleeding or ICH | 5.8% | 0.0% | 2.7% | 2.8% | 1.8% | 3.7% | | Renal failure | 17.5% | 13.0% | 7.9% | 10.6% | 5.8% | 8.4% | | Valve disease | 14.6% | 30.4% | 8.2% | 19.6% | 7.9% | 16.1% | | VTE | 7.8% | 43.5% | 5.1% | 30.7% | 3.9% | 25.3% | | AF | | | | | | | | No AF | 71.8% | 26.1% | 78.8% | 37.4% | 88.6% | 49.1% | | Prior but not current | 12.6% | 17.4% | 3.9% | 5.6% | 3.7% | 7.0% | | Prior and current | 6.8% | 30.4% | 3.0% | 22.4% | 2.8% | 23.1% | | New onset | 8.7% | 26.1% | 14.3% | 34.6% | 4.9% | 20.9% | | Charlson Comorbidity Index (mean ± std) | 7.6 ± 4.53 | 8.1 ± 4.04 | 6.4 ± 3.93 | 8.2 ± 3.86 | 5.7 ± 3.76 | 7.6 ± 3.87 | | Mechanical value | 0.0% | 0.0% | 0.1% | 1.7% | 0.2% | 0.4% | | Presentation | | | | | | | | Unstable angina | 70.9% | 56.5% | 49.1% | 35.2% | 39.8% | 27.1% | | STEMI | 3.9% | 0.0% | 6.0% | 8.9% | 14.9% | 22.7% | | Non-STEMI | 25.2% | 43.5% | 44.9% | 55.9% | 45.3% | 50.2% | | In-hospital procedures | | | | | | | | PCI without stent | 3.9% | 8.7% | 6.1% | 7.8% | 5.1% | 6.2% | | PCI with bare metal stent | 1.9% | 0.0% | 1.3% | 1.7% | 27.4% | 37.0% | | PCI with drug eluting stent | 1.0% | 4.3% | 2.7% | 2.8% | 61.5% | 50.2% | | CABG | 2.9% | 13.0% | 45.7% | 32.4% | 1.3% | 0.7% | | Number of vessels with CAD | | | | | | | | None | 30.1% | 43.5% | 18.8% | 29.1% | 3.9% | 7.0% | | Single | 15.5% | 13.0% | 14.8% | 22.3% | 44.1% | 35.2% | | Multiple | 54.4% | 43.5% | 66.4% | 48.6% | 52.0% | 57.9% | | Hospital length of stay (mean ± std) | 9.2 ± 8.32 | 11.1 ± 11.11 | 7.2 ± 6.93 | 11.4 ± 11.19 | 3.0 ± 3.50 | 6.1 ± 8.62 | | Hospital discharged home | 81.6% | 69.6% | 83.4% | 68.7% | 94.6% | 83.5% |
|
|
Note: AC: anticoagulant; CVD: cardiovascular disease; MI: myocardial infarction; COPD: chronic obstructive pulmonary disease; CVA: cerebral vascular accident; ICH: intracranial hemorrhage; VTE: vascular thrombus event; AF: atrial fibrillation; STEMI: ST elevated myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graph; CAD: coronary artery disease.
|
